


表5 ペルージャ大学の第1回パイロット臨床試験 (1993-1995)

(Aversa F の論文 24 の Table 1 を転載)

Table 1
The first pilot study (1993-1995)

Conditioning regimen	T-cell depletion:	SBA and E-rosette															
 <p>TBI 8 Gy in single dose at 16 cGy/m Thiotepa 10 mg/kg Cyclophosphamide 50 mg/kg × 2 Rabbit ATG 5 mg/kg × 5</p>	<p>Graft composition: CD34⁺ CD3⁺</p> <p>Results Primary engraftment Secondary engraftment Overall engraftment Acute GvHD II-IV Chronic GvHD</p>	<p>BM + PBPC 10.8 × 10⁶ kg⁻¹ 2.2 × 10⁵ kg⁻¹</p> <p>29 (80%) 4 33 (92%) 6/32 (18%) 1/23 (4%)</p>															
	<table border="1"> <thead> <tr> <th></th> <th>AML</th> <th>All</th> </tr> </thead> <tbody> <tr> <td>Patients</td> <td>12</td> <td>24</td> </tr> <tr> <td>Median age</td> <td>26</td> <td>22</td> </tr> <tr> <td>CR ≥ II</td> <td>3</td> <td>14</td> </tr> <tr> <td>Relapse</td> <td>9</td> <td>10</td> </tr> </tbody> </table>		AML	All	Patients	12	24	Median age	26	22	CR ≥ II	3	14	Relapse	9	10	<p>Disease-free survivors: AML 5/12 ALL 1/24</p>
	AML	All															
Patients	12	24															
Median age	26	22															
CR ≥ II	3	14															
Relapse	9	10															